Trexquant Investment LP Makes New $1.49 Million Investment in Zymeworks Inc. (NYSE:ZYME)

Trexquant Investment LP purchased a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 101,996 shares of the company's stock, valued at approximately $1,493,000. Trexquant Investment LP owned about 0.15% of Zymeworks as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of ZYME. AlphaQuest LLC boosted its holdings in shares of Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock valued at $41,000 after buying an additional 2,324 shares during the last quarter. FMR LLC lifted its stake in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after acquiring an additional 1,525 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Zymeworks in the 4th quarter valued at about $151,000. New York State Common Retirement Fund increased its stake in shares of Zymeworks by 42.7% during the 4th quarter. New York State Common Retirement Fund now owns 13,371 shares of the company's stock worth $196,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in shares of Zymeworks by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock valued at $201,000 after purchasing an additional 2,216 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Zymeworks Stock Performance

NYSE:ZYME traded up $0.32 during mid-day trading on Tuesday, reaching $11.32. 69,388 shares of the company's stock were exchanged, compared to its average volume of 620,125. The firm has a market capitalization of $787.26 million, a PE ratio of -7.53 and a beta of 1.18. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70. The business's fifty day simple moving average is $12.60 and its two-hundred day simple moving average is $13.56.

Insider Activity

In related news, Director Ecor1 Capital, Llc purchased 19,748 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The shares were bought at an average price of $13.87 per share, for a total transaction of $273,904.76. Following the completion of the transaction, the director now owns 15,720,161 shares of the company's stock, valued at approximately $218,038,633.07. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders acquired 1,335,171 shares of company stock worth $16,132,884. Corporate insiders own 1.92% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ZYME shares. Lifesci Capital initiated coverage on Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Citigroup lifted their target price on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Wells Fargo & Company increased their price target on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. HC Wainwright lifted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Monday, March 10th. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective on the stock in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.